Pembrolizumab and Chemotherapy Combination Prolonged Progression-Free Survival in Patients with NSCLC with High PD-L1 Expression and Low Neutrophil-to-Lymphocyte Ratio

• Main Authors: Jeng-Shiuan Tsai (Author), Sheng-Huan Wei (Author), Chian-Wei Chen (Author), Szu-Chun Yang (Author), Yau-Lin Tseng (Author), Po-Lan Su (Author), Chien-Chung Lin (Author), Wu-Chou Su (Author)
• Format: Book
• Published: MDPI AG, 2022-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The use of immune checkpoint inhibitors (ICIs) has provided overall survival (OS) benefits in patients with treatment-naïve advanced non-small cell lung cancer (NSCLC) without targetable driver mutations. However, studies comparing ICIs monotherapy with combination therapy either with chemotherapy o...